Phagocytosis checkpoints as new targets for cancer immunotherapy

[1]  O. Akilov,et al.  Targeting CD47 in Sézary syndrome with SIRPαFc. , 2019, Blood advances.

[2]  T. Schumacher,et al.  Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRPα axis and target for cancer immunotherapy , 2019, Nature Medicine.

[3]  Tie-niu Song,et al.  Tumor-derived exosomal HMGB1 promotes esophageal squamous cell carcinoma progression through inducing PD1+ TAM expansion , 2019, Oncogenesis.

[4]  R. Fehrmann,et al.  Cancer cell-expressed SLAMF7 is not required for CD47-mediated phagocytosis , 2019, Nature Communications.

[5]  I. Weissman,et al.  Microglia are effector cells of CD47-SIRPα antiphagocytic axis disruption against glioblastoma , 2019, Proceedings of the National Academy of Sciences.

[6]  I. Weissman,et al.  First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  L. Sever,et al.  SLAMF receptors on normal and malignant B cells. , 2019, Clinical immunology.

[8]  B. Rini,et al.  Emerging Role of Combination Immunotherapy in the First-line Treatment of Advanced Renal Cell Carcinoma: A Review , 2019, JAMA Oncology.

[9]  S. M. Toor,et al.  Immune checkpoint inhibitors: recent progress and potential biomarkers , 2018, Experimental & Molecular Medicine.

[10]  Michael P Snyder,et al.  Identification of phagocytosis regulators using magnetic genome-wide CRISPR screens , 2018, Nature Genetics.

[11]  I. Weissman,et al.  CD47 Blockade by Hu5F9‐G4 and Rituximab in Non‐Hodgkin's Lymphoma , 2018, The New England journal of medicine.

[12]  Sathish Kumar Mungamuri,et al.  Blocking immunoinhibitory receptor LILRB2 reprograms tumor-associated myeloid cells and promotes antitumor immunity , 2018, The Journal of clinical investigation.

[13]  E. Winer,et al.  Atezolizumab and Nab‐Paclitaxel in Advanced Triple‐Negative Breast Cancer , 2018, The New England journal of medicine.

[14]  Emily K. Lehrman,et al.  CD47 Protects Synapses from Excess Microglia-Mediated Pruning during Development , 2018, Neuron.

[15]  C. Zhang,et al.  A Novel Anti-LILRB4 CAR-T Cell for the Treatment of Monocytic AML. , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

[16]  J. Allison,et al.  Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. , 2018, Cancer discovery.

[17]  M. Atkins,et al.  Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain , 2018, The New England journal of medicine.

[18]  Benjamin P. C. Chen,et al.  LILRB4 signaling in leukemia cells mediates T cell suppression and tumor infiltration , 2018, Nature.

[19]  I. Weissman,et al.  Programmed cell removal by calreticulin in tissue homeostasis and cancer , 2018, Nature Communications.

[20]  T. Yap,et al.  Efficacy and Toxic Effects of Cancer Immunotherapy Combinations-A Double-edged Sword. , 2018, JAMA oncology.

[21]  yang-xin fu,et al.  Dual Targeting of Innate and Adaptive Checkpoints on Tumor Cells Limits Immune Evasion. , 2018, Cell reports.

[22]  R. Beijersbergen,et al.  Neutrophils Kill Antibody-Opsonized Cancer Cells by Trogoptosis. , 2018, Cell reports.

[23]  Zhijian J. Chen,et al.  The cGAS–cGAMP–STING pathway connects DNA damage to inflammation, senescence, and cancer , 2018, The Journal of experimental medicine.

[24]  M. Robinson,et al.  ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial. , 2018, The Lancet. Oncology.

[25]  J. Szustakowski,et al.  Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden , 2018, The New England journal of medicine.

[26]  T. Schumacher,et al.  T Cell Dysfunction in Cancer. , 2018, Cancer cell.

[27]  Bohuslav Melichar,et al.  Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal‐Cell Carcinoma , 2018, The New England journal of medicine.

[28]  A. Veillette,et al.  SIRPα-CD47 Immune Checkpoint Blockade in Anticancer Therapy. , 2018, Trends in immunology.

[29]  Ying Sun,et al.  Human Semaphorin-4A drives Th2 responses by binding to receptor ILT-4 , 2018, Nature Communications.

[30]  V. D’Agati,et al.  ILT3.Fc–CD166 Interaction Induces Inactivation of p70 S6 Kinase and Inhibits Tumor Cell Growth , 2018, The Journal of Immunology.

[31]  Juan Li,et al.  Circular DNA: a stable probe for highly efficient mRNA imaging and gene therapy in living cells. , 2018, Chemical communications.

[32]  I. Weissman,et al.  Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy , 2017, Nature Immunology.

[33]  P. Ascierto,et al.  Anti-PD-1 and PD-L1 antibodies in metastatic melanoma. , 2017, Melanoma management.

[34]  I. Weissman,et al.  Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity , 2017, Proceedings of the National Academy of Sciences.

[35]  V. Lee,et al.  TTI-621 (SIRPαFc), a CD47-blocking cancer immunotherapeutic, triggers phagocytosis of lymphoma cells by multiple polarized macrophage subsets , 2017, PloS one.

[36]  D. Schadendorf,et al.  Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma , 2017, The New England journal of medicine.

[37]  Tarek Mekhail,et al.  Durvalumab after Chemoradiotherapy in Stage III Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.

[38]  D. Carbone,et al.  First-Line Nivolumab in Stage IV or Recurrent Non-Small Cell Lung Cancer , 2017 .

[39]  M. Stern,et al.  Micronuclei Frequency in Tumors Is a Predictive Biomarker for Genetic Instability and Sensitivity to the DNA Repair Inhibitor AsiDNA. , 2017, Cancer research.

[40]  R. Weichselbaum,et al.  Dendritic Cells but Not Macrophages Sense Tumor Mitochondrial DNA for Cross‐priming through Signal Regulatory Protein &agr; Signaling , 2017, Immunity.

[41]  Martin A. M. Reijns,et al.  cGAS surveillance of micronuclei links genome instability to innate immunity , 2017, Nature.

[42]  Dennis E Discher,et al.  Mitotic progression following DNA damage enables pattern recognition within micronuclei , 2017, Nature.

[43]  M. Socinski,et al.  First‐Line Nivolumab in Stage IV or Recurrent Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.

[44]  Shu-Hsia Chen,et al.  LILRB receptor-mediated regulation of myeloid cell maturation and function , 2017, Cancer Immunology, Immunotherapy.

[45]  C. N. Coleman,et al.  DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity , 2017, Nature Communications.

[46]  Daniel M. Corey,et al.  PD-1 expression by tumor-associated macrophages inhibits phagocytosis and tumor immunity , 2017, Nature.

[47]  A. Santoro,et al.  Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. , 2017, The Lancet. Oncology.

[48]  J. Danska,et al.  SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via Mac-1 integrin , 2017, Nature.

[49]  Irving L. Weissman,et al.  Unifying mechanism for different fibrotic diseases , 2017, Proceedings of the National Academy of Sciences.

[50]  P. Sharma,et al.  Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. , 2017, The Lancet. Oncology.

[51]  I. Weissman,et al.  A CD47-associated super-enhancer links pro-inflammatory signalling to CD47 upregulation in breast cancer , 2017, Nature Communications.

[52]  Jeffrey A. Engelman,et al.  Prospects for combining targeted and conventional cancer therapy with immunotherapy , 2017, Nature Reviews Cancer.

[53]  E. Plimack,et al.  Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. , 2017, The Lancet. Oncology.

[54]  Joe Y. Chang,et al.  Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy. , 2017, Cancer research.

[55]  Z. Johnson,et al.  Selective Blockade of the Ubiquitous Checkpoint Receptor CD47 Is Enabled by Dual-Targeting Bispecific Antibodies , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[56]  Alberto Mantovani,et al.  Tumour-associated macrophages as treatment targets in oncology , 2017, Nature Reviews Clinical Oncology.

[57]  R. Bourgon,et al.  Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial , 2017, The Lancet.

[58]  L. Zitvogel,et al.  Immunogenic cell death in cancer and infectious disease , 2016, Nature Reviews Immunology.

[59]  H. Tseng,et al.  BRAF/MEK inhibitors promote CD47 expression that is reversible by ERK inhibition in melanoma. , 2017, Oncotarget.

[60]  Federico Garrido,et al.  Rejection versus escape: the tumor MHC dilemma , 2017, Cancer Immunology, Immunotherapy.

[61]  T. Kurosaki,et al.  Tolerogenic immunoreceptor ILT3/LILRB4 paradoxically marks pathogenic auto-antibody-producing plasmablasts and plasma cells in non-treated SLE. , 2016, International immunology.

[62]  S. Trudel,et al.  TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding , 2016, Clinical Cancer Research.

[63]  K. Rock,et al.  Present Yourself! By MHC Class I and MHC Class II Molecules. , 2016, Trends in immunology.

[64]  Y. Shentu,et al.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.

[65]  Zhijian J. Chen,et al.  Regulation and function of the cGAS–STING pathway of cytosolic DNA sensing , 2016, Nature Immunology.

[66]  K. Zen,et al.  Cd47-Sirpα interaction and IL-10 constrain inflammation-induced macrophage phagocytosis of healthy self-cells , 2016, Proceedings of the National Academy of Sciences.

[67]  Andrew H. Beck,et al.  Antibody Therapy Targeting CD47 and CD271 Effectively Suppresses Melanoma Metastasis in Patient-Derived Xenografts. , 2016, Cell reports.

[68]  I. Weissman,et al.  CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer. , 2016, The Journal of clinical investigation.

[69]  Jens-Peter Volkmer,et al.  CD47 blocking antibodies restore phagocytosis and prevent atherosclerosis , 2016, Nature.

[70]  Özlem Türeci,et al.  Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy , 2016, Nature.

[71]  G. Freeman,et al.  Coinhibitory Pathways in Immunotherapy for Cancer. , 2016, Annual review of immunology.

[72]  R. Bourgon,et al.  Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial , 2016, The Lancet.

[73]  I. Weissman,et al.  Anti-CD47 Treatment Stimulates Phagocytosis of Glioblastoma by M1 and M2 Polarized Macrophages and Promotes M1 Polarized Macrophages In Vivo , 2016, PloS one.

[74]  Drew M. Pardoll,et al.  PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. , 2016, The New England journal of medicine.

[75]  K. Garcia,et al.  Durable antitumor responses to CD47 blockade require adaptive immune stimulation , 2016, Proceedings of the National Academy of Sciences.

[76]  Y. Shentu,et al.  Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial , 2016, The Lancet.

[77]  D. Felsher,et al.  MYC regulates the antitumor immune response through CD47 and PD-L1 , 2016, Science.

[78]  A. Ribas,et al.  Combination cancer immunotherapies tailored to the tumour microenvironment , 2016, Nature Reviews Clinical Oncology.

[79]  C. Zhang,et al.  Inhibitory leukocyte immunoglobulin-like receptors: Immune checkpoint proteins and tumor sustaining factors , 2015, Cell cycle.

[80]  Lewis L. Lanier,et al.  NK cells and cancer: you can teach innate cells new tricks , 2015, Nature Reviews Cancer.

[81]  N. Gül,et al.  Antibody-Dependent Phagocytosis of Tumor Cells by Macrophages: A Potent Effector Mechanism of Monoclonal Antibody Therapy of Cancer. , 2015, Cancer research.

[82]  A. Ravaud,et al.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.

[83]  J. Cambier,et al.  Of ITIMs, ITAMs, and ITAMis: revisiting immunoglobulin Fc receptor signaling , 2015, Immunological reviews.

[84]  G. Semenza,et al.  HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells , 2015, Proceedings of the National Academy of Sciences.

[85]  J. Cyster,et al.  Splenic Dendritic Cells Survey Red Blood Cells for Missing Self-CD47 to Trigger Adaptive Immune Responses. , 2015, Immunity.

[86]  P. Campbell,et al.  Somatic mutation in cancer and normal cells , 2015, Science.

[87]  I. Weissman,et al.  Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential , 2015, PloS one.

[88]  A. Ribas.  Adaptive Immune Resistance: How Cancer Protects from Immune Attack. , 2015, Cancer discovery.

[89]  yang-xin fu,et al.  CD47 Blockade Triggers T cell-mediated Destruction of Immunogenic Tumors , 2015, Nature Medicine.

[90]  R. Sullivan,et al.  Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy. , 2015, Seminars in oncology.

[91]  R. Majeti,et al.  A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells , 2015, mAbs.

[92]  Matthew Meyerson,et al.  CHROMOTHRIPSIS FROM DNA DAMAGE IN MICRONUCLEI , 2015, Nature.

[93]  J. Lunceford,et al.  Pembrolizumab for the treatment of non-small-cell lung cancer. , 2015, The New England journal of medicine.

[94]  B. Nilsson,et al.  Antagonistic human FcγRIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo. , 2015, Cancer cell.

[95]  Sky W. Brubaker,et al.  Innate immune pattern recognition: a cell biological perspective. , 2015, Annual review of immunology.

[96]  Yingyu Mao,et al.  Regulation of phagocytosis by Rho GTPases , 2015, Small GTPases.

[97]  E. Wherry,et al.  Overcoming T cell exhaustion in infection and cancer. , 2015, Trends in immunology.

[98]  H. Groen,et al.  Immunoglobulin-like transcript 3 is expressed by myeloid-derived suppressor cells and correlates with survival in patients with non-small cell lung cancer , 2015, Oncoimmunology.

[99]  P. Parren,et al.  Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma , 2015, mAbs.

[100]  H. Schild,et al.  Protein kinase CK2 enables regulatory T cells to suppress excessive TH2 responses in vivo , 2015, Nature Immunology.

[101]  Michael Ruogu Zhang,et al.  Macrophages eat cancer cells using their own calreticulin as a guide: Roles of TLR and Btk , 2015, Proceedings of the National Academy of Sciences.

[102]  J. Berzofsky,et al.  CD47 in the tumor microenvironment limits cooperation between antitumor T-cell immunity and radiotherapy. , 2014, Cancer research.

[103]  R. Weichselbaum,et al.  STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors. , 2014, Immunity.

[104]  Sanjiv S. Gambhir,et al.  Endoscopic molecular imaging of human bladder cancer using a CD47 antibody , 2014, Science Translational Medicine.

[105]  J. Murnane,et al.  DNA-damage response during mitosis induces whole-chromosome missegregation. , 2014, Cancer discovery.

[106]  N. Rogers,et al.  Thrombospondin-1 and CD47 regulation of cardiac, pulmonary and vascular responses in health and disease. , 2014, Matrix biology : journal of the International Society for Matrix Biology.

[107]  Lieping Chen,et al.  Inducible Expression of B7-H1 (PD-L1) and Its Selective Role in Tumor Site Immune Modulation , 2014, Cancer journal.

[108]  T. K. van den Berg,et al.  The interaction between signal regulatory protein alpha (SIRPα) and CD47: structure, function, and therapeutic target. , 2014, Annual review of immunology.

[109]  P. Kubes,et al.  Macrophages eliminate circulating tumor cells after monoclonal antibody therapy. , 2014, The Journal of clinical investigation.

[110]  S. Ferrone,et al.  Abstract 632: Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing , 2014 .

[111]  T. K. van den Berg,et al.  Of macrophages and red blood cells; a complex love story , 2013, Front. Physiol..

[112]  Kui Li,et al.  Toll-Like Receptors in Antiviral Innate Immunity , 2013, Journal of Molecular Biology.

[113]  M. van Egmond,et al.  Fc receptor-dependent mechanisms of monoclonal antibody therapy of cancer. , 2014, Current topics in microbiology and immunology.

[114]  S. Akira,et al.  Microbial sensing by Toll-like receptors and intracellular nucleic acid sensors. , 2014, Cold Spring Harbor perspectives in biology.

[115]  A. Celada,et al.  The Exonuclease Trex1 Restrains Macrophage Proinflammatory Activation , 2013, The Journal of Immunology.

[116]  C. Klein,et al.  Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab. , 2013, Blood.

[117]  Lu Zhang,et al.  Intravenous delivery of siRNA targeting CD47 effectively inhibits melanoma tumor growth and lung metastasis. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[118]  F. Dammacco,et al.  MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells. , 2013, Journal of the National Cancer Institute.

[119]  Jens-Peter Volkmer,et al.  Engineered SIRPα Variants as Immunotherapeutic Adjuvants to Anticancer Antibodies , 2013, Science.

[120]  Annie Bruns,et al.  Radiation‐induced loss of cell surface CD47 enhances immune‐mediated clearance of human papillomavirus‐positive cancer , 2013, International journal of cancer.

[121]  R. Kiessling,et al.  Immunogenic tumor cell death induced by chemoradiotherapy: molecular mechanisms and a clinical translation , 2013, Cell Death and Disease.

[122]  Jens-Peter Volkmer,et al.  Anti-CD47 antibody–mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response , 2013, Proceedings of the National Academy of Sciences.

[123]  W. Thomas,et al.  Bruton's Tyrosine Kinase Is Required for Apoptotic Cell Uptake via Regulating the Phosphorylation and Localization of Calreticulin , 2013, The Journal of Immunology.

[124]  I. Weissman,et al.  Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes , 2013, Proceedings of the National Academy of Sciences.

[125]  Abhishek D. Garg,et al.  Immunogenic cell death and DAMPs in cancer therapy , 2012, Nature Reviews Cancer.

[126]  Amin R. Mazloom,et al.  Gene-expression profiles and transcriptional regulatory pathways that underlie the identity and diversity of mouse tissue macrophages , 2012, Nature Immunology.

[127]  D. Wink,et al.  CD47 deficiency confers cell and tissue radioprotection by activation of autophagy , 2012, Autophagy.

[128]  Daigo Hashimoto,et al.  Deciphering the transcriptional network of the DC lineage , 2012, Nature Immunology.

[129]  C. Drake,et al.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.

[130]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[131]  P. Bruhns.  Properties of mouse and human IgG receptors and their contribution to disease models. , 2012, Blood.

[132]  I. Weissman,et al.  The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications. , 2012, Current opinion in immunology.

[133]  E. Ward,et al.  Inhibitory receptors bind Angptls and support blood stem cells and leukemia development , 2012, Nature.

[134]  Jens-Peter Volkmer,et al.  The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors , 2012, Proceedings of the National Academy of Sciences.

[135]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[136]  G. Dranoff,et al.  Combining immunotherapy and targeted therapies in cancer treatment , 2012, Nature Reviews Cancer.

[137]  I. Weissman,et al.  Programmed cell removal: a new obstacle in the road to developing cancer , 2011, Nature Reviews Cancer.

[138]  F. Bertucci,et al.  CD47–signal regulatory protein-α (SIRPα) interactions form a barrier for antibody-mediated tumor cell destruction , 2011, Proceedings of the National Academy of Sciences.

[139]  Des C. Jones,et al.  HLA Class I Allelic Sequence and Conformation Regulate Leukocyte Ig-Like Receptor Binding , 2011, The Journal of Immunology.

[140]  Ash A. Alizadeh,et al.  Calreticulin Is the Dominant Pro-Phagocytic Signal on Multiple Human Cancers and Is Counterbalanced by CD47 , 2010, Science Translational Medicine.

[141]  Ash A. Alizadeh,et al.  Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma , 2010, Cell.

[142]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[143]  M. Cragg,et al.  Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. , 2010, Blood.

[144]  Jennifer Sims,et al.  Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies , 2010, mAbs.

[145]  A. Iwasaki,et al.  Regulation of Adaptive Immunity by the Innate Immune System , 2010, Science.

[146]  Patrizia Agostinis,et al.  Immunogenic cell death, DAMPs and anticancer therapeutics: an emerging amalgamation. , 2010, Biochimica et biophysica acta.

[147]  D. Wink,et al.  Radioprotection in Normal Tissue and Delayed Tumor Growth by Blockade of CD47 Signaling , 2009, Science Translational Medicine.

[148]  Howard Y. Chang,et al.  Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells , 2009, Proceedings of the National Academy of Sciences.

[149]  I. Weissman,et al.  CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis , 2009, Cell.

[150]  Ash A. Alizadeh,et al.  CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells , 2009, Cell.

[151]  J. Geddes,et al.  What is a randomised controlled trial? , 2009, Epidemiologia e Psichiatria Sociale.

[152]  Shizuo Akira,et al.  The roles of TLRs, RLRs and NLRs in pathogen recognition. , 2009, International immunology.

[153]  C. Abram,et al.  The ins and outs of leukocyte integrin signaling. , 2009, Annual review of immunology.

[154]  R. Medzhitov,et al.  Toll-like receptors and cancer , 2009, Nature Reviews Cancer.

[155]  E. Itoi,et al.  Inhibitory Immunoglobulin-Like Receptors LILRB and PIR-B Negatively Regulate Osteoclast Development1 , 2008, The Journal of Immunology.

[156]  G. Newton,et al.  Endothelial CD47 interaction with SIRPgamma is required for human T-cell transendothelial migration under shear flow conditions in vitro. , 2008, Blood.

[157]  M. Rubio,et al.  CD47 Expression on T Cell Is a Self-Control Negative Regulator of Type 1 Immune Response1 , 2008, The Journal of Immunology.

[158]  L. Zitvogel,et al.  The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death , 2008, Cell Death and Differentiation.

[159]  D. Roberts,et al.  CD47: a new target in cardiovascular therapy. , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[160]  Dennis E. Discher,et al.  Inhibition of “self” engulfment through deactivation of myosin-II at the phagocytic synapse between human cells , 2008, The Journal of cell biology.

[161]  C. Geczy,et al.  Differential Expression of Leukocyte Immunoglobulin-like Receptors on Cord Blood-derived Human Mast Cell Progenitors and Mature Mast Cells , 2022 .

[162]  J. Ravetch,et al.  Fcγ receptors as regulators of immune responses , 2008, Nature Reviews Immunology.

[163]  D. Roberts,et al.  A New Target in Cardiovascular Therapy , 2008 .

[164]  P. van Endert,et al.  Ecto‐calreticulin in immunogenic chemotherapy , 2007, Immunological reviews.

[165]  L. Zitvogel,et al.  Leveraging the immune system during chemotherapy: moving calreticulin to the cell surface converts apoptotic death from "silent" to immunogenic. , 2007, Cancer research.

[166]  V. D’Agati,et al.  Soluble Ig-Like Transcript 3 Inhibits Tumor Allograft Rejection in Humanized SCID Mice and T Cell Responses in Cancer Patients1 , 2007, The Journal of Immunology.

[167]  L. Zitvogel,et al.  Calreticulin exposure dictates the immunogenicity of cancer cell death , 2007, Nature Medicine.

[168]  Michael Karin,et al.  Intracellular pattern recognition receptors in the host response , 2006, Nature.

[169]  Brown Mh,et al.  The SIRP family of receptors and immune regulation. , 2006 .

[170]  K. Camphausen,et al.  Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy , 2006, The Journal of experimental medicine.

[171]  H. Katz.  Inhibition of inflammatory responses by leukocyte Ig-like receptors. , 2006, Advances in immunology.

[172]  R. Clynes,et al.  Cell surface recycling of internalized antigen permits dendritic cell priming of B cells. , 2005, Immunity.

[173]  W. Janssen,et al.  Cell-Surface Calreticulin Initiates Clearance of Viable or Apoptotic Cells through trans-Activation of LRP on the Phagocyte , 2005, Cell.

[174]  I. Jutras,et al.  Phagocytosis: at the crossroads of innate and adaptive immunity. , 2005, Annual review of cell and developmental biology.

[175]  G. McFadden,et al.  Myxoma virus M128L is expressed as a cell surface CD47-like virulence factor that contributes to the downregulation of macrophage activation in vivo. , 2005, Virology.

[176]  C. Bertozzi,et al.  Glycans in cancer and inflammation — potential for therapeutics and diagnostics , 2005, Nature Reviews Drug Discovery.

[177]  Joanna D. Holbrook,et al.  Human Lymphocytes Interact Directly with CD47 through a Novel Member of the Signal Regulatory Protein (SIRP) Family1 , 2004, The Journal of Immunology.

[178]  D. Mancini,et al.  Alloantigen specific CD8+CD28- FOXP3+ T suppressor cells induce ILT3+ ILT4+ tolerogenic endothelial cells, inhibiting alloreactivity. , 2004, International immunology.

[179]  G. Dranoff,et al.  Cytokines in cancer pathogenesis and cancer therapy , 2004, Nature Reviews Cancer.

[180]  J. Pollard.  Tumour-educated macrophages promote tumour progression and metastasis , 2004, Nature Reviews Cancer.

[181]  B. Neel,et al.  The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. , 2003, Trends in biochemical sciences.

[182]  S. Akira,et al.  Toll-like receptors. , 2003, Annual review of immunology.

[183]  P. Gane,et al.  Evidence that the red cell skeleton protein 4.2 interacts with the Rh membrane complex member CD47. , 2003, Blood.

[184]  M. Walport,et al.  Role of Surfactant Proteins A, D, and C1q in the Clearance of Apoptotic Cells In Vivo and In Vitro: Calreticulin and CD91 as a Common Collectin Receptor Complex1 , 2002, The Journal of Immunology.

[185]  H. Krutzsch,et al.  Interactions of thrombospondins with α4β1 integrin and CD47 differentially modulate T cell behavior , 2002, The Journal of cell biology.

[186]  Charles A. Janeway,et al.  Decoding the Patterns of Self and Nonself by the Innate Immune System , 2002, Science.

[187]  M. Colonna,et al.  Tolerization of dendritic cells by TS cells: the crucial role of inhibitory receptors ILT3 and ILT4 , 2002, Nature Immunology.

[188]  V. Fadok,et al.  C1q and Mannose Binding Lectin Engagement of Cell Surface Calreticulin and Cd91 Initiates Macropinocytosis and Uptake of Apoptotic Cells , 2001, The Journal of experimental medicine.

[189]  R. Rebres,et al.  Normal Ligand Binding and Signaling by CD47 (Integrin-associated Protein) Requires a Long Range Disulfide Bond between the Extracellular and Membrane-spanning Domains* , 2001, The Journal of Biological Chemistry.

[190]  J. Coleman.  Nitric oxide in immunity and inflammation. , 2001, International immunopharmacology.

[191]  A. Ullrich,et al.  Signal-regulatory protein alpha (SIRPalpha) but not SIRPbeta is involved in T-cell activation, binds to CD47 with high affinity, and is expressed on immature CD34(+)CD38(-) hematopoietic cells. , 2001, Blood.

[192]  E. Brown,et al.  Integrin-associated protein (CD47) and its ligands. , 2001, Trends in cell biology.

[193]  P. Srivastava,et al.  CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. , 2001, Immunity.

[194]  D. Wiley,et al.  T Cell Receptor–MHC Interactions up Close , 2001, Cell.

[195]  H. Sterling,et al.  CD47, a Ligand for the Macrophage Fusion Receptor, Participates in Macrophage Multinucleation* , 2000, The Journal of Biological Chemistry.

[196]  C. Ober,et al.  HLA-G in reproduction: studies on the maternal-fetal interface. , 2000, Human immunology.

[197]  S. Matsuda,et al.  Molecular cloning of a novel human gene (SIRP-B2) which encodes a new member of the SIRP/SHPS-1 protein family , 2000, Journal of Human Genetics.

[198]  H. Kettenmann,et al.  Phagocytic Clearance of Apoptotic Neurons by Microglia/Brain Macrophages In Vitro , 2000, Journal of neurochemistry.

[199]  J. Verweij,et al.  Achievements and future of chemotherapy. , 2000, European journal of cancer.

[200]  A. Ullrich,et al.  Association of signal‐regulatory proteins β  with KARAP/DAP‐12 , 2000 .

[201]  A. Barclay,et al.  CD47 is a ligand for rat macrophage membrane signal regulatory protein SIRP (OX41) and human SIRPα 1 , 2000, European journal of immunology.

[202]  C. Lagenaur,et al.  Role of CD47 as a marker of self on red blood cells. , 2000, Science.

[203]  L. Presta,et al.  Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets , 2000, Nature Medicine.

[204]  M. Colonna,et al.  Cutting Edge: Signal-Regulatory Protein β1 Is a DAP12-Associated Activating Receptor Expressed in Myeloid Cells1 , 2000, The Journal of Immunology.

[205]  A. Ullrich,et al.  Association of signal-regulatory proteins beta with KARAP/DAP-12. , 2000, European journal of immunology.

[206]  A. Ullrich,et al.  Human signal-regulatory protein is expressed on normal, but not on subsets of leukemic myeloid cells and mediates cellular adhesion involving its counterreceptor CD47. , 1999, Blood.

[207]  C. Lagenaur,et al.  Integrin-associated Protein Is a Ligand for the P84 Neural Adhesion Molecule* , 1999, The Journal of Biological Chemistry.

[208]  A. Aderem,et al.  Mechanisms of phagocytosis in macrophages. , 1999, Annual review of immunology.

[209]  C. Maliszewski,et al.  The MHC class I binding proteins LIR‐1 and LIR‐2 inhibit Fc receptor‐mediated signaling in monocytes , 1998, European journal of immunology.

[210]  S. Latour,et al.  High Expression of Inhibitory Receptor SHPS-1 and Its Association with Protein-tyrosine Phosphatase SHP-1 in Macrophages* , 1998, The Journal of Biological Chemistry.

[211]  J. Solheim,et al.  Calreticulin and calnexin interact with different protein and glycan determinants during the assembly of MHC class I. , 1998, Journal of immunology.

[212]  Xue-qing Wang,et al.  The Thrombospondin Receptor CD47 (IAP) Modulates and Associates with α2β1 Integrin in Vascular Smooth Muscle Cells , 1998 .

[213]  G. Ogg,et al.  Human myelomonocytic cells express an inhibitory receptor for classical and nonclassical MHC class I molecules. , 1998, Journal of immunology.

[214]  R. Salter,et al.  Distinct patterns of folding and interactions with calnexin and calreticulin in human class I MHC proteins with altered N-glycosylation. , 1998, Journal of immunology.

[215]  K. Krause,et al.  Calreticulin , 1996, Molecular Biology Intelligence Unit.

[216]  M. Daëron,et al.  Fc receptor biology. , 2003, Annual review of immunology.

[217]  M. Kubin,et al.  A family of human lymphoid and myeloid Ig-like receptors, some of which bind to MHC class I molecules. , 1997, Journal of immunology.

[218]  M. Colonna,et al.  A Common Inhibitory Receptor for Major Histocompatibility Complex Class I Molecules on Human Lymphoid and Myelomonocytic Cells , 1997, The Journal of experimental medicine.

[219]  A. DeFranco,et al.  A Critical Role for Syk in Signal Transduction and Phagocytosis Mediated by Fcγ Receptors on Macrophages , 1997, The Journal of experimental medicine.

[220]  Manfred Brockhaus,et al.  A Novel Inhibitory Receptor (ILT3) Expressed on Monocytes, Macrophages, and Dendritic Cells Involved in Antigen Processing , 1997, The Journal of experimental medicine.

[221]  A. Ullrich,et al.  A family of proteins that inhibit signalling through tyrosine kinase receptors , 1997, Nature.

[222]  M. Colonna,et al.  Cloning of novel immunoglobulin superfamily receptors expressed on human myeloid and lymphoid cells: Structural evidence for new stimulatory and inhibitory pathways , 1997, European journal of immunology.

[223]  M. Deckert,et al.  Integrin-associated protein (CD47) is a comitogenic molecule on CD3-activated human T cells. , 1997, Journal of immunology.

[224]  P. Allen,et al.  Costimulation of T Cell Activation by Integrin-associated Protein (CD47) Is an Adhesion-dependent, CD28-independent Signaling Pathway , 1997, The Journal of experimental medicine.

[225]  M. Kasuga,et al.  A novel membrane glycoprotein, SHPS-1, that binds the SH2-domain-containing protein tyrosine phosphatase SHP-2 in response to mitogens and cell adhesion , 1996, Molecular and cellular biology.

[226]  M. Kasuga,et al.  Characterization of a 115-kDa Protein That Binds to SH-PTP2, a Protein-tyrosine Phosphatase with Src Homology 2 Domains, in Chinese Hamster Ovary Cells* , 1996, The Journal of Biological Chemistry.

[227]  Eric J. Brown,et al.  Decreased Resistance to Bacterial Infection and Granulocyte Defects in IAP-Deficient Mice , 1996, Science.

[228]  P. Budde,et al.  Tyrosine-containing sequence motifs of the human immunoglobulin G receptors FcRIIb1 and FcRIIb2 essential for endocytosis and regulation of calcium flux in B cells. , 1994, The Journal of biological chemistry.

[229]  I. Weissman,et al.  bcl-2 inhibits apoptosis of neutrophils but not their engulfment by macrophages , 1994, The Journal of experimental medicine.

[230]  E. Schwarz,et al.  Molecular cloning of integrin-associated protein: an immunoglobulin family member with multiple membrane-spanning domains implicated in alpha v beta 3-dependent ligand binding , 1993, The Journal of cell biology.

[231]  T. Honjo,et al.  Induced expression of PD‐1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. , 1992, The EMBO journal.

[232]  W. Foulkes,et al.  An ovarian tumor marker with homology to vaccinia virus contains an IgV-like region and multiple transmembrane domains. , 1992, Cancer research.

[233]  H. Gresham,et al.  Integrin-associated protein: a 50-kD plasma membrane antigen physically and functionally associated with integrins , 1990, The Journal of cell biology.

[234]  S. Hakomori,et al.  Aberrant glycosylation in tumors and tumor-associated carbohydrate antigens. , 1989, Advances in cancer research.

[235]  F. Garrido,et al.  Tumour immunology: MHC antigens and malignancy , 1986, Nature.

[236]  A. Wyllie,et al.  Macrophage recognition of cells undergoing programmed cell death (apoptosis). , 1985, Immunology.

[237]  R. C. Macridis.  A review , 1963 .